Loading news...
ArrowMark Colorado Holdings LLC lessened its position in QuidelOrtho Corporation (NASDAQ: QDEL) by 18.8% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 782,954 shares of the company's stock after selling 181,325 shares during the period. ArrowMark Colorado Holdings LLC owned about 1.15% of
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?
Rice Hall James purchased 574,877 shares of QuidelOrtho stock in the fourth quarter. The quarter-end position value grew by $16.2 million, reflecting both additional shares and price changes.
A board director at QuidelOrtho Corp. acquired 10,000 common shares on Feb. 13, 2026, at an average price of around $23.96 per share, totaling ~$240,000. All shares were acquired for direct ownership; indirect holdings via UGMA accounts and Birchview Fund, LLC, remain unchanged at 54,775 shares.
SAN DIEGO, Feb. 19, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, has released episode 56 of its Science Bytes podcast, featuring Dr. Lindy Carlstrom, Global Medical Affairs Manager for Acute Care. In this episode, Carlstrom and host Josh Casey discuss how high-sensitivity troponin (hs troponin) is transforming early cardiac diagnosis and improving emergency department efficiency.
SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of its management team will present at the Raymond James 47th Annual Institutional Investor Conference. The Company's presentation is scheduled for Tuesday, March 3, 2026, at 1:40 p.m.
Public Sector Pension Investment Board lifted its stake in shares of QuidelOrtho Corporation (NASDAQ: QDEL) by 17.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 264,853 shares of the company's stock after buying an additional 38,935 shares during the quarter. Public
QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.
/PRNewswire/ -- QuidelOrtho ha firmado un acuerdo de suministro estratégico a largo plazo con Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd.,
/PRNewswire/ -- QuidelOrtho ist mit Lifotronic Technology Co., Ltd. eine langfristige strategische Liefervereinbarung eingegangen (Lifotronic Technology Co.,
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Profitability This table compares QuidelOrtho and Oramed Pharmaceuticals'
QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to improve by over $200 million ― SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced financial results for the fourth quarter and full-year ended December 28, 2025. "In 2025, we transitioned from COVID-driven volatility to a more durable, diversified diagnostics business," said Brian J.
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
– First medical device company to receive excellence recognition in accordance with ISO 23592 – Gold Stevie® Award for Customer Service Success – Bronze Stevie® Award for AI & Tech Focused Digital Transformation Team of the Year SAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") received the Excellence Services Label for its Customer and Technical Services in EMEA, awarded by the independent association Esprit de Service France, and in accordance with the international standard ISO 23592, a global framework for designing and delivering outstanding customer experiences. QuidelOrtho is the first medical device company to receive this distinction.
SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine. With decades of experience in blood banking and immunohematology, Mullens shares insights into the pressures on today's blood supply and the importance of consistent donor engagement.
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its financial results for the fourth quarter and full year 2025 ended December 28, 2025, after the market close on Wednesday, February 11, 2026. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.
QDEL's decent Q3 2025 results and expanding diagnostics portfolio support near-term growth despite respiratory reliance and payer risks.